Literature DB >> 22210239

Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls.

Andrea T White1, Alan R Light, Ronald W Hughen, Timothy A Vanhaitsma, Kathleen C Light.   

Abstract

OBJECTIVE: Chronic fatigue syndrome (CFS) and multiple sclerosis (MS) are characterized by debilitating fatigue, yet evaluation of this symptom is subjective. We examined metabolite-detecting, adrenergic, and immune gene expression (messenger ribonucleic acid [mRNA]) in patients with CFS (n = 22) versus patients with MS (n = 20) versus healthy controls (n = 23) and determined their relationship to fatigue and pain before and after exercise.
METHODS: Blood samples and fatigue and pain ratings were obtained at baseline and 0.5, 8, 24, and 48 hours after sustained moderate exercise. Leukocyte mRNA of four metabolite-detecting receptors (acid-sensing ion channel 3, purinergic type 2X4 and 2X5 receptors, and transient receptor potential vanilloid type 1) and four adrenergic (α-2a, β-1, and β-2 receptors and catechol-O-methyltransferase) and five immune markers (CD14, toll-like receptor 4 [TLR4], interleukin [IL] 6, IL-10, and lymphotoxin α) was examined using quantitative polymerase chain reaction.
RESULTS: Patients with CFS had greater postexercise increases in fatigue and pain (10-29 points above baseline, p < .001) and greater mRNA increases in purinergic type 2X4 receptor, transient receptor potential vanilloid type 1, CD14, and all adrenergic receptors than controls (mean ± standard error = 1.3 ± 0.14- to 3.4 ± 0.90-fold increase above baseline, p = .04-.005). Patients with CFS with comorbid fibromyalgia (n = 18) also showed greater increases in acid-sensing ion channel 3 and purinergic type 2X5 receptors (p < .05). Patients with MS had greater postexercise increases than controls in β-1 and β-2 adrenergic receptor expressions (1.4 ± 0.27- and 1.3 ± 0.06-fold increases, respectively, p = .02 and p < .001) and greater decreases in TLR4 (p = .02). In MS, IL-10 and TLR4 decreases correlated with higher fatigue scores.
CONCLUSIONS: Postexercise mRNA increases in metabolite-detecting receptors were unique to patients with CFS, whereas both patients with MS and patients with CFS showed abnormal increases in adrenergic receptors. Among patients with MS, greater fatigue was correlated with blunted immune marker expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22210239      PMCID: PMC3256093          DOI: 10.1097/PSY.0b013e31824152ed

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  51 in total

1.  Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?

Authors:  C Heesen; L Nawrath; C Reich; N Bauer; K-H Schulz; S M Gold
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

2.  Cyclin-dependent kinase 5 modulates nociceptive signaling through direct phosphorylation of transient receptor potential vanilloid 1.

Authors:  Tej K Pareek; Jason Keller; Sashi Kesavapany; Nitin Agarwal; Rohini Kuner; Harish C Pant; Michael J Iadarola; Roscoe O Brady; Ashok B Kulkarni
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-28       Impact factor: 11.205

3.  Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia.

Authors:  Raffaello Furlan; Simona Colombo; Francesca Perego; Fabiola Atzeni; Alessandro Diana; Franca Barbic; Alberto Porta; Fabio Pace; Alberto Malliani; Piercarlo Sarzi-Puttini
Journal:  J Rheumatol       Date:  2005-09       Impact factor: 4.666

4.  The influence of aerobic fitness and fibromyalgia on cardiorespiratory and perceptual responses to exercise in patients with chronic fatigue syndrome.

Authors:  Dane B Cook; Paul R Nagelkirk; Ashok Poluri; John Mores; Benjamin H Natelson
Journal:  Arthritis Rheum       Date:  2006-10

5.  Ambulatory monitoring of physical activity and symptoms in fibromyalgia and chronic fatigue syndrome.

Authors:  Willem J Kop; Angela Lyden; Ali A Berlin; Kirsten Ambrose; Cara Olsen; Richard H Gracely; David A Williams; Daniel J Clauw
Journal:  Arthritis Rheum       Date:  2005-01

Review 6.  Exercise and multiple sclerosis.

Authors:  Lesley J White; Rudolph H Dressendorfer
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

7.  Differential diagnosis of chronic fatigue syndrome and major depressive disorder.

Authors:  Caroline Hawk; Leonard A Jason; Susan Torres-Harding
Journal:  Int J Behav Med       Date:  2006

Review 8.  Autonomic dysfunction in multiple sclerosis.

Authors:  Carl-Albrecht Haensch; Johannes Jörg
Journal:  J Neurol       Date:  2006-02       Impact factor: 4.849

9.  Is a full recovery possible after cognitive behavioural therapy for chronic fatigue syndrome?

Authors:  Hans Knoop; Gijs Bleijenberg; Marieke F M Gielissen; Jos W M van der Meer; Peter D White
Journal:  Psychother Psychosom       Date:  2007       Impact factor: 17.659

10.  Impact of aerobic training on fitness and quality of life in multiple sclerosis.

Authors:  J H Petajan; E Gappmaier; A T White; M K Spencer; L Mino; R W Hicks
Journal:  Ann Neurol       Date:  1996-04       Impact factor: 10.422

View more
  24 in total

Review 1.  Biomarkers for chronic fatigue.

Authors:  Nancy G Klimas; Gordon Broderick; Mary Ann Fletcher
Journal:  Brain Behav Immun       Date:  2012-06-23       Impact factor: 7.217

2.  Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome.

Authors:  Kathleen C Light; Neeraj Agarwal; Eli Iacob; Andrea T White; Anita Y Kinney; Timothy A VanHaitsma; Hannah Aizad; Ronald W Hughen; Lucinda Bateman; Alan R Light
Journal:  Psychoneuroendocrinology       Date:  2013-09-06       Impact factor: 4.905

3.  Comparing Genomic Profiles of Women With and Without Fibromyalgia.

Authors:  Nada Lukkahatai; Brian Walitt; Alexandra Espina; Dan Wang; Leorey N Saligan
Journal:  Biol Res Nurs       Date:  2015-05-26       Impact factor: 2.522

4.  Chronic Fatigue Syndrome: The Current Status and Future Potentials of Emerging Biomarkers.

Authors:  David Benjamin Fischer; Arsani Hany William; Adam Campbell Strauss; Elizabeth R Unger; Leonard Jason; Gailen D Marshall; Jordan D Dimitrakoff
Journal:  Fatigue       Date:  2014-06-01

5.  Fatigue sensation and gene expression in trained cyclists following a 40 km time trial in the heat.

Authors:  Timothy A VanHaitsma; Alan R Light; Kathleen C Light; Ronald W Hughen; Sarah Yenchik; Andrea T White
Journal:  Eur J Appl Physiol       Date:  2015-12-24       Impact factor: 3.078

6.  Do cognitive and physical fatigue tasks enhance pain, cognitive fatigue, and physical fatigue in people with fibromyalgia?

Authors:  Dana L Dailey; Valerie J Keffala; Kathleen A Sluka
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-02       Impact factor: 4.794

7.  Genetics and Gene Expression Involving Stress and Distress Pathways in Fibromyalgia with and without Comorbid Chronic Fatigue Syndrome.

Authors:  Kathleen C Light; Andrea T White; Scott Tadler; Eli Iacob; Alan R Light
Journal:  Pain Res Treat       Date:  2011-09-29

8.  The status of and future research into Myalgic Encephalomyelitis and Chronic Fatigue Syndrome: the need of accurate diagnosis, objective assessment, and acknowledging biological and clinical subgroups.

Authors:  Frank N M Twisk
Journal:  Front Physiol       Date:  2014-03-27       Impact factor: 4.566

Review 9.  Neuroendocrine immunoregulation in multiple sclerosis.

Authors:  Nathalie Deckx; Wai-Ping Lee; Zwi N Berneman; Nathalie Cools
Journal:  Clin Dev Immunol       Date:  2013-12-08

10.  Acid-sensing ion channels 1a (ASIC1a) inhibit neuromuscular transmission in female mice.

Authors:  Francisco J Urbano; Noelia G Lino; Carlota M F González-Inchauspe; Laura E González; Natalia Colettis; Lucas G Vattino; Amanda M Wunsch; John A Wemmie; Osvaldo D Uchitel
Journal:  Am J Physiol Cell Physiol       Date:  2013-12-11       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.